48,830
edits
Difference between revisions of "Urothelial carcinoma"
Jump to navigation
Jump to search
→IHC
(→IHC) |
(→IHC) |
||
| Line 117: | Line 117: | ||
*CK20 negative in over 50% of cases with metastases.<ref name=pmid11419977>{{Cite journal | last1 = Jiang | first1 = J. | last2 = Ulbright | first2 = TM. | last3 = Younger | first3 = C. | last4 = Sanchez | first4 = K. | last5 = Bostwick | first5 = DG. | last6 = Koch | first6 = MO. | last7 = Eble | first7 = JN. | last8 = Cheng | first8 = L. | title = Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. | journal = Arch Pathol Lab Med | volume = 125 | issue = 7 | pages = 921-3 | month = Jul | year = 2001 | doi = 10.1043/0003-9985(2001)1250921:CACIPU2.0.CO;2 | PMID = 11419977 }}</ref> | *CK20 negative in over 50% of cases with metastases.<ref name=pmid11419977>{{Cite journal | last1 = Jiang | first1 = J. | last2 = Ulbright | first2 = TM. | last3 = Younger | first3 = C. | last4 = Sanchez | first4 = K. | last5 = Bostwick | first5 = DG. | last6 = Koch | first6 = MO. | last7 = Eble | first7 = JN. | last8 = Cheng | first8 = L. | title = Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. | journal = Arch Pathol Lab Med | volume = 125 | issue = 7 | pages = 921-3 | month = Jul | year = 2001 | doi = 10.1043/0003-9985(2001)1250921:CACIPU2.0.CO;2 | PMID = 11419977 }}</ref> | ||
==Reactive changes versus UCIS== | ===Reactive changes versus UCIS=== | ||
:''See [[urothelial carcinoma in situ]]''. | :''See [[urothelial carcinoma in situ]]''. | ||
==UCC versus other== | ===UCC versus other=== | ||
UCC vs. [[Prostate cancer|prostate]]: | UCC vs. [[Prostate cancer|prostate]]: | ||
*UCC: GATA3 +ve, PSA -ve, [[p63]] +ve, [[CK20]] +ve. | *UCC: GATA3 +ve, PSA -ve, [[p63]] +ve, [[CK20]] +ve. | ||
| Line 128: | Line 128: | ||
*UCC: p63 +ve.<ref>{{Cite journal | last1 = Langner | first1 = C. | last2 = Ratschek | first2 = M. | last3 = Tsybrovskyy | first3 = O. | last4 = Schips | first4 = L. | last5 = Zigeuner | first5 = R. | title = P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. | journal = J Histochem Cytochem | volume = 51 | issue = 8 | pages = 1097-9 | month = Aug | year = 2003 | doi = | PMID = 12871991 }} | *UCC: p63 +ve.<ref>{{Cite journal | last1 = Langner | first1 = C. | last2 = Ratschek | first2 = M. | last3 = Tsybrovskyy | first3 = O. | last4 = Schips | first4 = L. | last5 = Zigeuner | first5 = R. | title = P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. | journal = J Histochem Cytochem | volume = 51 | issue = 8 | pages = 1097-9 | month = Aug | year = 2003 | doi = | PMID = 12871991 }} | ||
</ref> | </ref> | ||
Metastatic UCC versus primary lung SCC: | |||
*See ''[[Squamous_cell_carcinoma_of_the_lung#Lung_SCC_versus_metastatic_bladder_urothelial_carcinoma]]''. | |||
Note: | Note: | ||
| Line 133: | Line 136: | ||
</ref> | </ref> | ||
**In half the cases the staining is weak and in the other half it is strong.<ref name=pmid19192675/> | **In half the cases the staining is weak and in the other half it is strong.<ref name=pmid19192675/> | ||
=Staging= | =Staging= | ||